(CNN) The antimalarial drug hydroxychloroquine did not benefit non-hospitalized patients with mild Covid-19 symptoms who were treated early in their infection, according to a study published Thursday in the medical journal Annals of Internal Medicine. Previous randomized clinical trials in the United States had looked at hydroxychloroquine as prevention, or as treatment for hospitalized coronavirus patients. Half the patients received five days of hydroxychloroquine treatment and half the patients received five days of a placebo. About 24% of the hydroxychloroquine group had symptoms that persisted over 14 days, compared to the 30% who took the placebo. And, 43% of those who took hydroxychloroquine had side effects, compared to the 22% that took a placebo.

Source: CNN July 16, 2020 19:18 UTC